Optimizing Pazopanib Exposure in RCC Patients through Therapeutic Drug Monitoring Followed by Intrapatient Dose Escalation
Phase of Trial: Phase II
Latest Information Update: 21 Aug 2017
At a glance
- Drugs Pazopanib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms OPERA
- 30 Aug 2016 Planned End Date changed from 1 Jun 2016 to 1 Dec 2016.
- 14 Apr 2016 Status changed from recruiting to discontinued.
- 14 May 2014 New source identified and integrated (ClinicalTrials.gov record: NCT02089802)